Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Brunswick Corporation (BC) vs TransMedics Group Inc (TMDX) Price & Performance

Brunswick CorporationTrade
TransMedics Group IncTrade

Price performance (Past 24H)

Key statistics

Brunswick Corporation vs TransMedics Group Inc — how do they compare? Brunswick Corporation trades at $79.6 (market cap $5.04B), while TransMedics Group Inc trades at $76.2 (market cap $2.58B). The key difference: Brunswick Corporation is the larger of the two by market cap, and Brunswick Corporation pays a 2.27% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.

BCTMDX
Market Cap
$5.04B$2.58B
Sector
Consumer CyclicalTechnology
52-Week High
$89.22$150.42
52-Week Low
$56.64$61.99
Enterprise Value
$7.20B$2.98B
Dividend Yield
2.27%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Brunswick Corporation

BC's stock trades at $76.95, down 1.22% on the day, with a bearish technical signal and support near $76. The company reported a net loss of $137.30 million in 2025 despite revenue of $5.36 billion, though recent earnings beat expectations. Analyst consensus is strongly bullish with a $86.40 price target, and the company continues expanding its Freedom Boat Club business.

The outlook is mixed: strong analyst support and operational cash flow of $562.10 million in 2025 provide upside potential, but negative profit margins and high P/E of 73.92 pose valuation risks. Investors face headwinds from profitability challenges despite positive sentiment from Wall Street.

TransMedics Group Inc

TransMedics (TMDX) trades at $75.74, up 6.33% today, showing strong momentum despite a recent earnings miss. The stock maintains bullish technical signals with support at $75 and resistance at $77. Recent strategic investments in European organ logistics through PAD Aviation position the company for international expansion, though margin pressure from these investments remains a concern. Analyst consensus remains strongly positive with a $108.71 price target.

The outlook remains favorable with 75% analyst buy ratings and significant upside potential from current levels. Key risks include execution challenges in European expansion, ongoing margin pressure from NOP investments, and competitive threats in the transplant logistics space. Revenue growth continues at 21% year-over-year, but investors should monitor margin trends and European rollout execution closely.

Returns comparison

Trailing returns across standard periods

About Brunswick Corporation

Brunswick Corp is the leader in several recreational sectors. The firm is the leading boat manufacturer, and its brands include Mercury and Mariner outboard engines

Read more on BC

About TransMedics Group Inc

TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.

Read more on TMDX